Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Afghanistan Veteran, PDF Champion to Complete Luxembourg IRONMAN for Parkinson’s Research on Saturday, June 20

US Army First Lieutenant Ashley Murray, a Piscataway, NJ, native, is running, biking and swimming to fight for a future without Parkinson’s disease. First Lt. Murray, an Afghanistan veteran who is currently stationed in Germany, will complete the Ergo IRONMAN 70.3 Luxembourg triathlon on Saturday, June 20 to raise funds for the Parkinson’s Disease Foundation (PDF).

First Lt. Murray, 25, is no stranger to physically challenging endeavors, having also been a member of Army ten-miler teams. Now, she is taking on the unique challenges of the IRONMAN as a way to contribute to the Parkinson’s cause. While 70.3 miles might be challenge enough for some, for First Lt. Murray it is just one of many she will face to help the Parkinson’s cause – with the next being medical school. First Lt. Murray has hopes of joining the medical profession as a neurologist in order to care for people living with Parkinson’s, a neurological disease, which she notes, has no cure and affects seven to 10 million people worldwide.

“I’m racing for PDF to show how passionate I am about helping people who live with Parkinson’s. I have always wanted to become a neurologist and am applying to medical school this year,” says First Lt. Murray. “I have competed in several endurance challenges, but after I came across an article on Parkinson's disease that led me to PDF’s website, I knew I wanted to dedicate a race to this cause.”

Working with the PDF Champions program, the grassroots fundraising arm of the Parkinson’s Disease Foundation, First Lt. Murray hopes to exceed her $2,000 fundraising goal. She says she is already more than halfway there thanks to the support of family and friends back home.

PDF President Robin Elliott added, “At PDF, we are grateful for PDF Champions like First Lt. Murray who are dedicated to funding the most promising research and raising awareness about the impact of Parkinson’s. Her efforts will help PDF to improve the lives and futures of the nearly one million people across the country living with Parkinson’s.”

Friday, May 29, 2015
In Memory of Robert Traurig
Wednesday, July 18, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member Robert (Bob) Traurig. From 2004 to 2015, he was a member of the Foundation’s board of directors. Bob is survived by his wife Jacqueline, his daughters Madeline Sackel and Wendy Traurig.

New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson’s Disease by 2030
Tuesday, July 10, 2018

Parkinson’s Foundation Reveals Most Comprehensive Estimate of
Parkinson’s Prevalence in North America since the 1970’s

Parkinson’s Foundation Elects Howard D. Morgan Chairman of the Board
Tuesday, June 26, 2018

MIAMI & NEW YORK — June 26, 2018 — The Parkinson’s Foundation today announced the election of Howard D. Morgan as chairman of its board of directors. Mr. Morgan, who previously served as the Vice Chair of the nonprofit organization’s board, is a Partner and the Senior Managing Director of Argand Partners in New York.

Parkinson’s Foundation Announces Five New Members of its People with Parkinson’s Advisory Council
Wednesday, June 13, 2018

NEW YORK & MIAMI — June 13, 2018 — The Parkinson’s Foundation today announced five new members of its People with Parkinson’s Advisory Council.

The Parkinson’s Foundation 2018 Gala in New York City Tuesday, May 8, 2018
Monday, May 14, 2018

The Parkinson’s Foundation 2018 Gala was held at Cipriani 25 Broadway in New York City on Tuesday, May 8, 2018.

Parkinson’s Foundation Adds Alison Herman to its Board of Directors
Tuesday, May 8, 2018

MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.

Statement on Nuplazid Drug
Tuesday, April 10, 2018

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

Parkinson’s Foundation Adds John D. Thomopoulos to its Board of Directors
Monday, March 19, 2018

MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.

In Memory of Edythe Kay Marsa
Monday, March 12, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care
Tuesday, March 6, 2018

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.